摘要
目的探讨肾素-血管紧张素-醛固酮系统(RAAS系统)在甲亢合并周期性麻痹患者131I治愈前后变化的临床意义。方法选取2011年3月至2014年3月就诊核医学科确诊甲亢并用131I治愈的病例295例,其中合并周期性麻痹患者54例为A组,不合并周期性麻痹患者241例为B组,测定其血清钾K+,甲状腺功能,RAAS系统水平变化。分别比较A组、B组于131I治疗前、131I治愈后血清钾、血浆甲状腺激素水平及血浆RAAS水平变化。结果131I治疗前A组和B组之间血浆RAAS水平差异有统计学意义(P<0.01),131I治愈后A组和B组之间血浆RAAS水平变化差异没有统计学意义(P>0.05)。结论甲亢合并周期性麻痹患者血浆RAAS系统水平升高可能是引起患者低血钾的一个原因,监测甲亢患者血浆RAAS系统水平变化对其是否合并周期性麻痹的预测判断有积极临床意义。
Objective To investigate the changes of level of plasma RAAS system ( PRA, AⅡ, ALD ) in hyperthyroidism with periodic paralysis patients before and after with 131I treatment and its clinical significance. Methods 295 cases of hyperthyroidism patients in which 54 cases of patienti with periodic paralysis ( Group A) and 241 cases without periodic paralysis( Group B)were involved in thislstudy, The serum potassium, plasma levels of thyroid hormones ( FT3, FT4, TSH ), plasma RAAS system ( PRA, A 11 , ALD ) level were determined before and after 131I treatment. Results There was significantly different on the plasma levels of RAAS between group A and group B before the 131I treatment(P 〈0.01). The changes of the plasma level of RAAS after 131I treatment between Group A and Group B had no statistical significance ( P 〉0. 05 ). Conclusion The increased level of plasma RAAS system ( PRA, A Ⅱ , ALD ) in hyperthyroidism with periodic paralysis patients may be a cause of low blood potassium, and the monitoring of plasma RAAS system levels might have clinical significance in the prediction judgment of patients of hyperthyroidism with periodic paralysis.
出处
《标记免疫分析与临床》
CAS
2016年第1期29-31,共3页
Labeled Immunoassays and Clinical Medicine